Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3214282 | 0.80 | CYP3A4 (0.49) | CTSSCYP3A4ADRB2HTR2AHTR2C | |
| SCHEMBL3210281 | 0.79 | CHRM4 (0.59) | CYP3A4ADRB2CHRM4 | |
| SCHEMBL3219331 | 0.79 | MCOLN3 (0.44) | CTSSCYP3A4 | |
| SCHEMBL3223542 | 0.78 | CYP3A4 (0.45) | CTSSCYP3A4ADRB2HTR2AHTR2C | |
| SCHEMBL3219342 | 0.78 | CYP3A4 (0.42) | CTSSCYP3A4ADRB2HCAR2 | |
| SCHEMBL3210443 | 0.77 | CYP3A4 (0.47) | CTSSCYP3A4ADRB2 | |
| SCHEMBL3221162 | 0.77 | CTSS (0.54) | CTSS | |
| SCHEMBL28039072 | 0.77 | ALDH1A1 (0.51) | CTSSHTR2AHTR2C | |
| SCHEMBL3210278 | 0.77 | MAPT (0.47) | CTSSCYP3A4ADRB2HTR2AHTR2C | |
| SCHEMBL5347507 | 0.75 | CHRM4 (0.61) | CYP3A4CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | CTSS 1997/4885CYP3A4 102/4885ADRB2 1062/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | CTSS 1885/4885CYP3A4 108/4885ADRB2 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.